Indication

For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Medicine details

Medicine name:
ublituximab (Briumvi)
SMC ID:
SMC2731
Pharmaceutical company
Neuraxpharm UK Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Publication due date:
13 January 2025